Gliatech
This article was originally published in The Gray Sheet
Executive Summary
Health Policy Associates hired as independent auditor to assist firm in responding to FDA's Application Integrity Policy (AIP) letter questioning post-market data for the Adcon-L gel anti-adhesion product for lumbar surgery. FDA recently suspended review of one premarket approval application and two PMA supplements submitted by the firm (1"The Gray Sheet" Jan. 1, 2001, p. 5)
You may also be interested in...
Adcon Data Will Be Evaluated By Third Party In Wake Of FDA Action - Gliatech
Gliatech will contract an independent evaluator to review magnetic resonance imaging data associated with postmarket studies of the company's Adcon-L gel anti-adhesion product for lumbar surgery.
Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Transformation Into Viatris Not Seen As The Solution Mylan Needs
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: